Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666848 · ClinicalTrials.gov registry record · Phase 4
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome
A Phase 4 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00666848 is a Phase 4 study that has completed, run by Vanderbilt University. The registered enrollment target is 24 participants.
The verdict
NCT00666848, a Phase 4 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Enalapril 5mg
- DRUG Enalapril 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666848
The ClinicalTrials.gov registry entry for NCT00666848 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00666848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666848 about?
NCT00666848 is a clinical study titled "Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome". This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.
What is the current status of trial NCT00666848?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2008-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00666848?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Enalapril 5mg (DRUG), Enalapril 10mg (DRUG).
Who is sponsoring clinical trial NCT00666848?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.